Kelly Vis1, Rick Waalboer-Spuij1,2, Dyon G C T M Snels3, Loes M Hollestein1,4. 1. Department of Dermatology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. 2. Department of Dermatology, Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands. 3. Department of Dermatology, Franciscus Gasthuis and Vlietland, Rotterdam, the Netherlands. 4. Netherlands Comprehensive Cancer Organization (IKNL), Netherlands Cancer Registry, Eindhoven, the Netherlands.
Abstract
BACKGROUND: The Actinic Keratosis Quality of Life Questionnaire (AKQoL) is a disease-specific instrument to measure the impact of actinic keratosis (AK) on patients' lives. OBJECTIVE: To validate and test the psychometric properties of the AKQoL translated into the Dutch language (AKQoL-NL). METHODS: All new patients ≥50 years of age with untreated AK in a university medical center and a general hospital between August 2014 and August 2015 were eligible. The AKQoL was obtained and repeated after 2 weeks. The feasibility was tested by missing responses and response distribution. The internal consistency reliability of each domain was investigated with the Cronbach alpha, and test-retest reliability and validity with the Spearman correlation coefficient. AKQoL scores were compared to the Skindex-17 for convergent validity and to the Groningen Frailty Indicator scores for divergent validity. RESULTS: A total of 153 of 190 eligible patients consented to participate. Feasibility analysis showed that none of the items missed ≥10% of responses but 5 of the 9 items showed floor effect. The AKQoL subscales showed a moderate internal consistency (Cronbach α = 0.235-0.468) and an excellent test-retest reliability (interclass correlation coefficient = 0.997-1). The AKQoL correlated poorly with the symptom component and moderately with the psychosocial component of the Skindex-17 (ρ = -0.015 to 0.346 and 0.324 to 0.501, respectively), which is less than expected. The AKQoL scored poorly in both of the Groningen Frailty Indicator (GFI) components (ρ = -0.97 to 0.12 and 0.185 to 0.276, respectively), as expected. CONCLUSION: The AKQoL-NL is a feasible, moderately valid, and moderately reliable health-related quality of life questionnaire.
BACKGROUND: The Actinic Keratosis Quality of Life Questionnaire (AKQoL) is a disease-specific instrument to measure the impact of actinic keratosis (AK) on patients' lives. OBJECTIVE: To validate and test the psychometric properties of the AKQoL translated into the Dutch language (AKQoL-NL). METHODS: All new patients ≥50 years of age with untreated AK in a university medical center and a general hospital between August 2014 and August 2015 were eligible. The AKQoL was obtained and repeated after 2 weeks. The feasibility was tested by missing responses and response distribution. The internal consistency reliability of each domain was investigated with the Cronbach alpha, and test-retest reliability and validity with the Spearman correlation coefficient. AKQoL scores were compared to the Skindex-17 for convergent validity and to the Groningen Frailty Indicator scores for divergent validity. RESULTS: A total of 153 of 190 eligible patients consented to participate. Feasibility analysis showed that none of the items missed ≥10% of responses but 5 of the 9 items showed floor effect. The AKQoL subscales showed a moderate internal consistency (Cronbach α = 0.235-0.468) and an excellent test-retest reliability (interclass correlation coefficient = 0.997-1). The AKQoL correlated poorly with the symptom component and moderately with the psychosocial component of the Skindex-17 (ρ = -0.015 to 0.346 and 0.324 to 0.501, respectively), which is less than expected. The AKQoL scored poorly in both of the Groningen Frailty Indicator (GFI) components (ρ = -0.97 to 0.12 and 0.185 to 0.276, respectively), as expected. CONCLUSION: The AKQoL-NL is a feasible, moderately valid, and moderately reliable health-related quality of life questionnaire.
Authors: Martin A Weinstock; Stephen F Bingham; John J Digiovanna; Amilcar E Rizzo; Kim Marcolivio; Russell Hall; David Eilers; Mark Naylor; Robert Kirsner; James Kalivas; Gary Cole; Julia E Vertrees Journal: J Invest Dermatol Date: 2012-02-09 Impact factor: 8.551
Authors: I Alarcon; G R Vinding; K B Christensen; S Esmann; J Malvehy; S Puig; G B E Jemec Journal: J Eur Acad Dermatol Venereol Date: 2017-02-27 Impact factor: 6.166
Authors: Sophie C Flohil; Robert J T van der Leest; Emmilia A Dowlatshahi; Albert Hofman; Esther de Vries; Tamar Nijsten Journal: J Invest Dermatol Date: 2013-03-19 Impact factor: 8.551
Authors: Marcella Akemi Haruno de Vilhena; Ivanka Miranda de Castro; Anna Carolina Miola; Ingrid Stresser Gioppo; Amanda Soares Teixeira; Hélio Amante Miot Journal: An Bras Dermatol Date: 2022-09-20 Impact factor: 2.113